DX 52-1 | CAS# 96251-59-1 | anthracycline

MedKoo Cat#: 413976 | Name: DX 52-1

Description:

WARNING: This product is for research use only, not for human or veterinary use.

DX 52-1 is an anticancer drug that is a type of antitumor antibiotic. It is an anthracycline.

Chemical Structure

DX 52-1

CAS#96251-59-1

Theoretical Analysis

MedKoo Cat#: 413976

Name: DX 52-1

CAS#: 96251-59-1

Chemical Formula: C19H23N3O4

Exact Mass: 357.1689

Molecular Weight: 357.41

Elemental Analysis: C, 63.85; H, 6.49; N, 11.76; O, 17.91

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

DX 52-1; DX52-1; DX 52-1

IUPAC/Chemical Name

8,11-Iminoazepino(1,2-b)isoquinoline-10-carboxylic acid, 7-cyano-5,7,8,9,10,11,11a,12-octahydro-5-(hydroxymethyl)-4-methoxy-13-methyl-

InChi Key

YGWHMSNGVVTUIT-UHFFFAOYSA-N

InChi Code

InChI=1S/C19H23N3O4/c1-21-12-7-11(19(24)25)18(21)13-6-10-4-3-5-16(26-2)17(10)15(9-23)22(13)14(12)8-20/h3-5,11-15,18,23H,6-7,9H2,1-2H3,(H,24,25)

SMILES Code

O=C(C(CC(N1C)C2C#N)C1C3N2C(CO)C4=C(C=CC=C4OC)C3)O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 357.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Kahsai AW, Zhu S, Wardrop DJ, Lane WS, Fenteany G. Quinocarmycin analog DX-52-1 inhibits cell migration and targets radixin, disrupting interactions of radixin with actin and CD44. Chem Biol. 2006 Sep;13(9):973-83. doi: 10.1016/j.chembiol.2006.07.011. PMID: 16984887. 2: Mirsalis JC, Schindler-Horvat J, Hill JR, Green CE, Mitoma C, Tomaszewski JE, Tyson CA, Donohue SJ. Toxicity of a quinocarmycin analog, DX-52-1, in rats and dogs in relation to clinical outcome. Cancer Chemother Pharmacol. 2003 Mar;51(3):193-201. doi: 10.1007/s00280-002-0553-0. Epub 2003 Jan 18. PMID: 12655436. 3: Plowman J, Dykes DJ, Narayanan VL, Abbott BJ, Saito H, Hirata T, Grever MR. Efficacy of the quinocarmycins KW2152 and DX-52-1 against human melanoma lines growing in culture kand in mice. Cancer Res. 1995 Feb 15;55(4):862-7. PMID: 7850800. 4: Bunnell CA, Supko JG, Eder JP Jr, Clark JW, Lynch TJ, Kufe DW, Shulman LN. Phase I clinical trial of 7-cyanoquinocarcinol (DX-52-1) in adult patients with refractory solid malignancies. Cancer Chemother Pharmacol. 2001 Nov;48(5):347-55. doi: 10.1007/s002800100319. PMID: 11761451. 5: Kahsai AW, Cui J, Kaniskan HU, Garner PP, Fenteany G. Analogs of tetrahydroisoquinoline natural products that inhibit cell migration and target galectin-3 outside of its carbohydrate-binding site. J Biol Chem. 2008 Sep 5;283(36):24534-45. doi: 10.1074/jbc.M800006200. Epub 2008 Jun 13. PMID: 18556657; PMCID: PMC2528994. 6: Brown LM, Cowen RL, Debray C, Eustace A, Erler JT, Sheppard FC, Parker CA, Stratford IJ, Williams KJ. Reversing hypoxic cell chemoresistance in vitro using genetic and small molecule approaches targeting hypoxia inducible factor-1. Mol Pharmacol. 2006 Feb;69(2):411-8. doi: 10.1124/mol.105.015743. Epub 2005 Oct 27. PMID: 16254058. 7: Clottes E. Le facteur induit par l'hypoxie HIF1: régulation, implication dans la carcinogenèse et cible thérapeutique anticancer [Hypoxia-inducible factor 1: regulation, involvement in carcinogenesis and target for anticancer therapy]. Bull Cancer. 2005 Feb;92(2):119-27. French. PMID: 15749641. 8: Fuse E, Nishiie H, Kobayashi H, Ikeda S, Saito H, Covey J, Kobayashi S. Disposition of DX-52-1, a novel anticancer agent, after intravenous administration to mice and dogs. Eur J Drug Metab Pharmacokinet. 1997 Jan- Mar;22(1):53-63. doi: 10.1007/BF03189785. PMID: 9179561. 9: Supko JG, Soglia JR, Nair RV. Assay for the quinocarmycin analog DX-52-1 in human plasma using high-performance liquid chromatography with automated column switching and low wavelength ultraviolet detection. J Chromatogr B Biomed Sci Appl. 1998 Sep 4;714(2):341-53. doi: 10.1016/s0378-4347(98)00214-x. PMID: 9766875. 10: Evensen NA, Li J, Yang J, Yu X, Sampson NS, Zucker S, Cao J. Development of a high-throughput three-dimensional invasion assay for anti-cancer drug discovery. PLoS One. 2013 Dec 11;8(12):e82811. doi: 10.1371/journal.pone.0082811. PMID: 24349367; PMCID: PMC3859626.